Our pipeline.
In curating the current portfolio, a premium was placed on pursuing programs with strong biological validation, mechanistic diversification, and teams with proprietary capabilities and insights. This framework has resulted in the current portfolio consisting of more than a dozen preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. In aggregate, we offer a portfolio that provides enhanced diversification with binary risk removed, and asymmetric upside that is equipped to withstand the inherent low probability of success associated with drug development of any single asset.
Overview
Palladio is developing lixivaptan, an oral non-peptide, new chemical agent that works by selectively suppressing the hormone vasopressin at the V2 receptor, as a treatment for autosomal dominant polycystic kidney disease with the goal of slowing the progression of kidney function decline and avoiding the liver safety issues associated with tolvaptan.
Target Validation
Precedented Human Activity
Overview
PegaOne is developing imgatuzumab, a humanized, non-fucosylated, anti-EGFR monoclonal antibody, for the treatment of cutaneous squamous cell carcinoma and other solid tumor indications.
Target Validation
Precedented Human Activity
Overview
ApcinteX is developing SerpinPC, a specific inhibitor of the anticoagulant protease activated protein C (APC), for the treatment for Hemophilia A and Hemophilia B, with or without inhibitors.
Target Validation
Human Genetics
Overview
Z Factor is developing ZF874, a small molecule chemical chaperone intended to rescue folding of the Z variant of alpha-1-antitrypsin, increasing serum levels of active protein and reducing accumulation in the liver, for the treatment of alpha-1-antitrypsin deficiency.
Target Validation
Human Genetics
Overview
Morphogen-IX is developing MGX292, a protein-engineered variant of human bone morphogenetic protein-9 (BMP9), for the treatment of pulmonary arterial hypertension.
Target Validation
Human Genetics
Overview
Capella Bioscience is developing CBS001, a neutralizing therapeutic monoclonal antibody to the inflammatory membrane form of LIGHT (known as TNFSF14), for the treatment of idiopathic pulmonary fibrosis.
Target Validation
Precedented Non-Clinical Activity
Overview
Capella Bioscience is developing CBS004, a therapeutic monoclonal antibody to blood dendritic cell antigen 2 (BDCA2), for the treatment of lupus erythematosus (systemic and cutaneous) and systemic sclerosis.
Target Validation
Precedented Human Activity
Overview
LockBody is pioneering a platform technology to develop LockBody CD47 (LB1) for optimal targeting of solid tumors by the innate immune system. LB1 is designed to bypass the CD47 sink, minimize peripheral toxicity and drive maximal CD47 intra-tumoral blocking activity.
Target Validation
Precedented Human Activity
Overview
LockBody is pioneering a platform technology to develop LockBody CD3 (LB2) for safe and effective targeting of solid tumors by the innate immune system. LB2 is designed to be gradually unlocked in the tumor microenvironment to allow for potent CD3 recruitment and T cell mediated killing.
Target Validation
Precedented Human Activity
Overview
Orexia is developing oral orexin receptor agonist small molecules that target Orexin Receptor-2 (OX2R) for the treatment of Narcolepsy Type 1 and other neurological disorders.
Target Validation
Precedented Human Activity
Overview
Orexia Therapeutics is developing intranasally administered Orexin Receptor-2 (OX2R) preferring peptides and intranasal OX2R small molecule agonists for the treatment of Narcolepsy Type 1 and other neurological disorders.
Target Validation
Precedented Human Activity
Overview
Janpix is developing a novel class of selective dual-STAT3/5 small molecule monovalent degraders for the treatment of hematological malignancies, including leukemias and lymphomas.
Target Validation
Human Genetics
Overview
PearlRiver Bio is developing oral EGFR C797S inhibitors for the treatment of patients with EGFR non small cell lung cancer who have acquired the C797S mutation following treatment with and resistance to EGFR TKIs.
Target Validation
Precedented Human Activity
Overview
PearlRiver Bio is developing potent and selective oral exon20 insertion mutation inhibitors intended to have minimal activity on wild-type EGFR and optimal pharmacokinetic properties, for the treatment of EGFR exon 20 insertion (with potential to target and treat Her2 exon 20 insertions) non small cell lung cancer.
Target Validation
Precedented Human Activity
Overview
PearlRiver Bio is developing undisclosed next generation EGFR inhibitors for the treatment of non small cell lung cancer.
Target Validation
Precedented Human Activity